Results 161 to 170 of about 12,153 (246)

Medication Burden: Beyond Counts to Recognize Polypharmacy as an Inherent Part of Living With Chronic Kidney Disease

open access: yesBasic &Clinical Pharmacology &Toxicology, Volume 139, Issue 2, August 2026.
ABSTRACT Medication burden in older patients with chronic kidney disease (CKD) is substantial, and simple medication counts are insufficient for identifying those at elevated risk of inappropriate prescribing. This study characterized medication burden by assessing the number of medications, potentially inappropriate medications (PIMs) and ...
Morten Baltzer Houlind   +4 more
wiley   +1 more source

Lithium Dispensing Patterns in Dutch Youth: Prevalence, Incidence Dosages, and Duration of Use From 2011 to 2022

open access: yesBipolar Disorders, Volume 28, Issue 5, August 2026.
ABSTRACT Objective Bipolar disorder (BD) often emerges during mid‐adolescence and young adulthood, and leads to functional and social impairment, with a prevalence of 0.87% among Dutch youth. Lithium, the first‐line BD maintenance treatment, stabilizes mood, prevents suicide, and is well tolerated, yet its use has declined as long‐term second ...
Ravish N. Gangapersad   +8 more
wiley   +1 more source

Psychotropic Prescribing Patterns Among Bipolar‐I Patients Prior to Established Bipolar‐I Disorder Diagnosis

open access: yesBipolar Disorders, Volume 28, Issue 5, August 2026.
ABSTRACT Objective Bipolar I Disorder (BP‐I) is frequently misdiagnosed as Major Depressive Disorder (MDD), delaying appropriate treatment. This study aimed to examine treatment patterns among BP‐I patients misdiagnosed with MDD and assess the impact of these regimens on the time until BP‐I diagnosis.
Filmon Haile   +2 more
wiley   +1 more source

S3 guideline diagnostics and therapy in alopecia areata – Part 2: Therapy, psychosocial and cosmetic support

open access: yesJDDG: Journal der Deutschen Dermatologischen Gesellschaft, Volume 24, Issue 8, Page e1155-e1177, August 2026.
Summary This second part of the S3 guideline on the diagnosis and treatment of alopecia areata (AA), presents key recommendations on topical and systemic therapy, quality of life and support services. The first part of the guideline, published separately, covers the definition and content of epidemiology and diagnosis as well as comorbidities, risk and
Ulrike Blume‐Peytavi   +13 more
wiley   +1 more source

High prevalence of polypharmacy and nervous system medications in people with HIV: a cross-sectional analysis. [PDF]

open access: yesSci Rep
López López A   +8 more
europepmc   +1 more source

Analgesic effects of alpha‐2‐adrenoreceptor agonists in equine medicine: systemic, spinal, and local applications

open access: yesEquine Veterinary Education, Volume 38, Issue 8, Page 442-452, August 2026.
Summary Alpha‐2‐adrenoreceptor agonists provide analgesia when used as sole agents but can also be used in combination with other drugs for their additive and potentially synergistic effects. Further, because of their effects on blood flow, alpha‐2‐adrenoreceptor agonists act to extend and perhaps intensify the effects of drugs, such as local ...
J. Brandly   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy